Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that Health Canada has approved RYBREVANT (amivantamab) in combination with chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations whose disease has progressed on osimertinib.

This approval is based on the Phase 3 MARIPOSA-2 study, which demonstrated a significant improvement in progression-free survival for patients receiving RYBREVANT plus chemotherapy compared to chemotherapy alone.

RYBREVANT offers a new treatment option for patients with EGFR-mutated NSCLC who have limited treatment options after progression on osimertinib.